Key Points
- Ra Capital Management sold about 2.21 million VOR shares in early April for roughly $36.6 million (including 53,644 shares on April 15 at $16.01), leaving it with 3,197,619 shares — a 1.65% reduction in its position valued at ≈$51.19 million.
- Vor Biopharma stock traded near $15.60 (1‑year range $2.62–$65.80) with a market cap of $762 million; analysts’ consensus is a “Moderate Buy” with an average price target of $50.56 and institutional ownership of 97.29%.
Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 53,644 shares of the firm's stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $16.01, for a total value of $858,840.44. Following the transaction, the director owned 3,197,619 shares in the company, valued at approximately $51,193,880.19. This represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Monday, April 13th, Ra Capital Management, L.P. sold 530,610 shares of Vor Biopharma stock. The shares were sold at an average price of $16.15, for a total value of $8,569,351.50.
- On Tuesday, April 14th, Ra Capital Management, L.P. sold 153,735 shares of Vor Biopharma stock. The shares were sold at an average price of $15.97, for a total value of $2,455,147.95.
- On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The shares were sold at an average price of $15.75, for a total value of $13,041.00.
- On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $2,242,984.59.
- On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The shares were sold at an average price of $16.48, for a total value of $7,978,033.92.
- On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63.
- On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The shares were sold at an average price of $18.23, for a total value of $4,739,800.00.
Vor Biopharma Price Performance
Shares of VOR stock opened at $15.60 on Thursday. Vor Biopharma Inc. has a 1-year low of $2.62 and a 1-year high of $65.80. The stock's 50-day moving average is $14.60 and its 200 day moving average is $16.68. The company has a market cap of $762.06 million, a P/E ratio of -0.04 and a beta of 1.92.
Institutional Investors Weigh In On Vor Biopharma
Institutional investors and hedge funds have recently modified their holdings of the company. Ariose Capital Management Ltd acquired a new stake in shares of Vor Biopharma during the third quarter worth about $5,368,000. Fcpm Iii Services B.V. acquired a new stake in shares of Vor Biopharma during the third quarter worth about $18,496,000. Susquehanna Portfolio Strategies LLC acquired a new stake in shares of Vor Biopharma during the fourth quarter worth about $134,000. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the second quarter worth about $66,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after purchasing an additional 58,247 shares during the period. Institutional investors and hedge funds own 97.29% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the company. TD Cowen assumed coverage on Vor Biopharma in a research report on Wednesday, December 17th. They set a "buy" rating on the stock. Wedbush raised their price target on Vor Biopharma to $15.00 and gave the stock a "neutral" rating in a report on Tuesday, March 31st. Citigroup began coverage on Vor Biopharma in a report on Friday, January 9th. They issued a "buy" rating and a $50.00 price target for the company. HC Wainwright lowered their price target on Vor Biopharma from $32.00 to $31.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Wells Fargo & Company began coverage on Vor Biopharma in a report on Thursday, March 19th. They issued an "overweight" rating and a $30.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Vor Biopharma currently has an average rating of "Moderate Buy" and a consensus price target of $50.56.
View Our Latest Report on VOR
Vor Biopharma Company Profile
(
Get Free Report)
Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.
The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
